---
document_datetime: 2025-12-17 23:10:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/yescarta.html
document_name: yescarta.html
version: success
processing_time: 0.1260214
conversion_datetime: 2025-12-28 14:50:04.786481
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Yescarta

[RSS](/en/individual-human-medicine.xml/65937)

##### Authorised

This medicine is authorised for use in the European Union

axicabtagene ciloleucel Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Yescarta](#news-on)
- [More information on Yescarta](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Yescarta is a medicine for treating adults with certain types of blood cancer:

- high-grade B-cell lymphoma (HGBL);
- diffuse large B-cell lymphoma (DLBCL);
- primary mediastinal large B-cell lymphoma (PMBCL);
- follicular lymphoma (FL).

Yescarta is for use in patients whose blood cancer has returned (recurrent) or has stopped responding to previous treatment (refractory).

Yescarta is a type of advanced therapy medicine called a 'gene therapy product'. This is a type of medicine that works by delivering genes into the body.

The blood cancers that Yescarta is used to treat are rare, and Yescarta was designated an 'orphan medicine' (a medicine used in rare diseases) for DLBCL on [16 December 2014](/en/medicines/human/orphan-designations/eu-3-14-1393) , for PMBCL on [9 October 2015](/en/medicines/human/orphan-designations/eu-3-15-1553) and for FL on [11 November 2015](/en/medicines/human/orphan-designations/eu-3-15-1579) .

Yescarta contains the active substance axicabtagene ciloleucel (consisting of genetically modified white blood cells).

Expand section

Collapse section

## How is Yescarta used?

Yescarta is prepared using the patient's own white blood cells which are extracted from the blood, genetically modified in the laboratory, and then given back to the patient.

It is given as a single infusion (drip) into a vein and must only be given to the patient whose cells were used to make it. Before having Yescarta, the patient should have a short course of chemotherapy to clear away their existing white blood cells, and just before the infusion they should be given paracetamol and an antihistamine medicine to reduce the risk of reactions to the infusion.

A medicine called tocilizumab (or a suitable alternative if this is unavailable due to a shortage) and emergency equipment must be available in case the patient has a potentially serious side effect called cytokine release syndrome (see risks section below).

Patients should be closely monitored for 10 days after treatment for side effects and are advised to stay close to a specialist hospital for at least 4 weeks after treatment.

For more information about using Yescarta, see the package leaflet or contact your doctor or pharmacist.

## How does Yescarta work?

Yescarta contains the patient's own T cells (a type of white blood cell) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). CAR can attach to another protein on the surface of cancer cells called CD19.

When Yescarta is given to the patient, the modified T cells attach to cancer cells and kill them, thereby helping to clear the cancer from the body.

## What benefits of Yescarta have been shown in studies?

**High-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) after one line of treatment**

A main study involving 359 patients with HGBL or DLBCL that had not responded to, or returned within a year of receiving one previous treatment, showed that Yescarta is effective at prolonging the time patients live without experiencing a certain event (worsening of disease, start of a new lymphoma therapy, or death). On average, patients given Yescarta were event-free for around 8 months, compared with 2 months for patients given standard cancer treatments. In addition, 41% of patients given Yescarta were event-free after 24 months of treatment, compared with 16% of patients receiving standard treatment.

**Diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) after two or more lines of treatment**

A main study of 111 patients with DLBCL and PMBCL that was not responding to two previous treatments or had returned showed that Yescarta is effective at clearing the cancer in many patients. Of the patients who joined the study, 47% had a complete response (which means they had no signs of the cancer left) and 66% had at least a partial response after treatment with Yescarta.

These results were better than those from studies of patients receiving standard cancer treatments, where around 7% of patients had a complete response and around 26% had at least a partial response.

**Follicular lymphoma (FL) after three or more lines of treatment**

A main study of 75 patients with FL that, after at least three previous treatments, was not responding or had returned showed that Yescarta is effective at clearing the cancer in many patients. Of these, 91% responded to the treatment, with 77% having a complete response.

These results were better than those seen in studies with patients receiving standard treatments for FL.

## What are the risks associated with Yescarta?

Serious side effects may occur in about 1 in 2 patients. The most common serious side effects are cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure), encephalopathy (a brain disorder associated with headache, sleepiness and mental confusion) and infections.

Yescarta must not be used in patients allergic to gentamicin (a type of antibiotic).  For the full list of side effects and restrictions with Yescarta, see the package leaflet.

## Why is Yescarta authorised in the EU?

A main study showed that Yescarta is effective at clearing the cancer in many patients with DLBCL, HGBL and PMBCL that was not responding to previous treatment or had returned. The number of patients who were cleared of the cancer or had at least a partial response was higher than in patients receiving standard care. Another study also showed that the medicine is effective at clearing the cancer in many patients with FL that, after at least three previous treatments, was not responding or had returned.

Serious side effects, particularly cytokine release syndrome, are common in patients being treated with Yescarta; however these are manageable if appropriate measures are in place (see below). The European Medicines Agency therefore decided that Yescarta's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Yescarta?

The company that markets Yescarta must ensure that hospitals where Yescarta is given have appropriate expertise, facilities and training. Tocilizumab or a suitable alternative must be available in case of cytokine release syndrome. The company must provide educational materials for healthcare professionals and patients about possible side effects, especially cytokine release syndrome.

The company must also carry out a study to obtain more information on the long term safety of Yescarta.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yescarta have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Yescarta are continuously monitored. Side effects reported with Yescarta are carefully evaluated and any necessary action taken to protect patients.

## Other information about Yescarta

Yescarta received a marketing authorisation valid throughout the EU on 23 August 2018.

Yescarta : EPAR - Medicine overview

Reference Number: EMA/854121/2022

English (EN) (148.77 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 16/12/2022

[View](/en/documents/overview/yescarta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-507)

български (BG) (175.66 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/bg/documents/overview/yescarta-epar-medicine-overview_bg.pdf)

español (ES) (149.48 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/es/documents/overview/yescarta-epar-medicine-overview_es.pdf)

čeština (CS) (174.44 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/cs/documents/overview/yescarta-epar-medicine-overview_cs.pdf)

dansk (DA) (147.18 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/da/documents/overview/yescarta-epar-medicine-overview_da.pdf)

Deutsch (DE) (152.67 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/de/documents/overview/yescarta-epar-medicine-overview_de.pdf)

eesti keel (ET) (135.14 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/et/documents/overview/yescarta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (179.22 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/el/documents/overview/yescarta-epar-medicine-overview_el.pdf)

français (FR) (150.94 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/fr/documents/overview/yescarta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (174.8 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/hr/documents/overview/yescarta-epar-medicine-overview_hr.pdf)

italiano (IT) (147.81 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/it/documents/overview/yescarta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (190.11 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/lv/documents/overview/yescarta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (171.48 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/lt/documents/overview/yescarta-epar-medicine-overview_lt.pdf)

magyar (HU) (175.83 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/hu/documents/overview/yescarta-epar-medicine-overview_hu.pdf)

Malti (MT) (175.02 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/mt/documents/overview/yescarta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (148.8 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/nl/documents/overview/yescarta-epar-medicine-overview_nl.pdf)

polski (PL) (175.08 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/pl/documents/overview/yescarta-epar-medicine-overview_pl.pdf)

português (PT) (149.75 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/pt/documents/overview/yescarta-epar-medicine-overview_pt.pdf)

română (RO) (172.61 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/ro/documents/overview/yescarta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (175.68 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/sk/documents/overview/yescarta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (170.03 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/sl/documents/overview/yescarta-epar-medicine-overview_sl.pdf)

Suomi (FI) (145.26 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/fi/documents/overview/yescarta-epar-medicine-overview_fi.pdf)

svenska (SV) (147.08 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

16/12/2022

[View](/sv/documents/overview/yescarta-epar-medicine-overview_sv.pdf)

Yescarta : EPAR - Risk management plan

English (EN) (3.27 MB - PDF)

**First published:** 10/09/2018

**Last updated:** 20/10/2025

[View](/en/documents/rmp/yescarta-epar-risk-management-plan_en.pdf)

## Product information

Yescarta : EPAR - Product Information

English (EN) (507.78 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 08/12/2025

[View](/en/documents/product-information/yescarta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-320)

български (BG) (843.5 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/bg/documents/product-information/yescarta-epar-product-information_bg.pdf)

español (ES) (629.25 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/es/documents/product-information/yescarta-epar-product-information_es.pdf)

čeština (CS) (772.92 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/cs/documents/product-information/yescarta-epar-product-information_cs.pdf)

dansk (DA) (625.41 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/da/documents/product-information/yescarta-epar-product-information_da.pdf)

Deutsch (DE) (666.77 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/de/documents/product-information/yescarta-epar-product-information_de.pdf)

eesti keel (ET) (612.75 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/et/documents/product-information/yescarta-epar-product-information_et.pdf)

ελληνικά (EL) (854.31 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/el/documents/product-information/yescarta-epar-product-information_el.pdf)

français (FR) (636.99 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/fr/documents/product-information/yescarta-epar-product-information_fr.pdf)

hrvatski (HR) (772.87 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/hr/documents/product-information/yescarta-epar-product-information_hr.pdf)

íslenska (IS) (611.44 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/is/documents/product-information/yescarta-epar-product-information_is.pdf)

italiano (IT) (622.56 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/it/documents/product-information/yescarta-epar-product-information_it.pdf)

latviešu valoda (LV) (794.56 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/lv/documents/product-information/yescarta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (757.56 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/lt/documents/product-information/yescarta-epar-product-information_lt.pdf)

magyar (HU) (763.52 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/hu/documents/product-information/yescarta-epar-product-information_hu.pdf)

Malti (MT) (813.79 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/mt/documents/product-information/yescarta-epar-product-information_mt.pdf)

Nederlands (NL) (620.57 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/nl/documents/product-information/yescarta-epar-product-information_nl.pdf)

norsk (NO) (595 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/no/documents/product-information/yescarta-epar-product-information_no.pdf)

polski (PL) (810.51 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/pl/documents/product-information/yescarta-epar-product-information_pl.pdf)

português (PT) (610.37 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/pt/documents/product-information/yescarta-epar-product-information_pt.pdf)

română (RO) (768.69 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/ro/documents/product-information/yescarta-epar-product-information_ro.pdf)

slovenčina (SK) (789.52 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/sk/documents/product-information/yescarta-epar-product-information_sk.pdf)

slovenščina (SL) (733.18 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/sl/documents/product-information/yescarta-epar-product-information_sl.pdf)

Suomi (FI) (635.95 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/fi/documents/product-information/yescarta-epar-product-information_fi.pdf)

svenska (SV) (644.79 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

08/12/2025

[View](/sv/documents/product-information/yescarta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000285857 13/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Yescarta : EPAR - All Authorised presentations

English (EN) (41.13 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 10/09/2018

[View](/en/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-124)

български (BG) (72.17 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/bg/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_bg.pdf)

español (ES) (81.81 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/es/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56.33 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/cs/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (89.97 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/da/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.01 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/de/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (96.22 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/et/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (116.24 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/el/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_el.pdf)

français (FR) (61.35 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/fr/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (85.25 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/hr/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (78 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/is/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.25 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/it/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (111.1 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/lv/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (113.56 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/lt/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (102.71 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/hu/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (74.9 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/mt/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (74.05 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/nl/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (62.97 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/no/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_no.pdf)

polski (PL) (100.14 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/pl/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_pl.pdf)

português (PT) (63.64 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/pt/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_pt.pdf)

română (RO) (63.44 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/ro/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (85.69 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/sk/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (91.9 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/sl/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (41.61 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/fi/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (72.5 KB - PDF)

**First published:**

10/09/2018

**Last updated:**

10/09/2018

[View](/sv/documents/all-authorised-presentations/yescarta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Yescarta Active substance axicabtagene ciloleucel International non-proprietary name (INN) or common name axicabtagene ciloleucel Therapeutic area (MeSH)

- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse

Anatomical therapeutic chemical (ATC) code L01XX70

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.

Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.

## Authorisation details

EMA product number EMEA/H/C/004480

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Kite Pharma EU B.V.

Tufsteen 1

Opinion adopted 28/06/2018 Marketing authorisation issued 23/08/2018 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Yescarta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (121.69 KB - PDF)

**First published:** 20/08/2025

**Last updated:** 08/12/2025

[View](/en/documents/procedural-steps-after/yescarta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Yescarta : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (241.26 KB - PDF)

**First published:** 23/01/2019

**Last updated:** 20/10/2025

[View](/en/documents/procedural-steps-after/yescarta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Yescarta : EPAR - Orphan Maintenance Assessment Report (post-authorisation)

Adopted

Reference Number: EMADOC-1700519818-943901

English (EN) (777.22 KB - PDF)

**First published:** 16/12/2022

[View](/en/documents/orphan-maintenance-report-post/yescarta-epar-orphan-maintenance-assessment-report-post-authorisation_en.pdf-0)

Yescarta-H-C-004480-II-0046 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/804955/2022

English (EN) (4.02 MB - PDF)

**First published:** 16/12/2022

[View](/en/documents/variation-report/yescarta-h-c-004480-ii-0046-epar-assessment-report-variation_en.pdf)

Yescarta-H-C-PSUSA-00010703-202110 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/936726/2022

English (EN) (126.65 KB - PDF)

**First published:** 12/12/2022

[View](/en/documents/scientific-conclusion/yescarta-h-c-psusa-00010703-202110-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Yescarta (II-46)

Adopted

Reference Number: EMA/CHMP/760015/2022

English (EN) (138.1 KB - PDF)

**First published:** 16/09/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-yescarta-ii-46_en.pdf)

Yescarta-H-C-004480-II-0042 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/622447/2022

English (EN) (2.86 MB - PDF)

**First published:** 12/07/2022

[View](/en/documents/variation-report/yescarta-h-c-004480-ii-0042-epar-assessment-report-variation_en.pdf)

Yescarta : EPAR - Orphan Maintenance Assessment Report (post authorisation)

Adopted

Reference Number: EMA/OD/0000068456

English (EN) (492.25 KB - PDF)

**First published:** 12/07/2022

[View](/en/documents/orphan-maintenance-report-post/yescarta-epar-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

CHMP post-authorisation summary of opinion for Yescarta (II-42)

Adopted

Reference Number: EMA/CHMP/222176/2022

English (EN) (218.24 KB - PDF)

**First published:** 22/04/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-yescarta-ii-42_en.pdf)

Yescarta-H-C-PSUSA-00010703-201904 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/52410/2020

English (EN) (139.07 KB - PDF)

**First published:** 03/02/2020

[View](/en/documents/scientific-conclusion/yescarta-h-c-psusa-00010703-201904-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Yescarta : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/511556/2018

English (EN) (232.71 KB - PDF)

**First published:** 10/09/2018

**Last updated:** 10/09/2018

[View](/en/documents/orphan-maintenance-report/yescarta-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Yescarta : EPAR - Public assessment report

Adopted

Reference Number: EMA/481168/2018

English (EN) (3.48 MB - PDF)

**First published:** 10/09/2018

[View](/en/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Yescarta

Adopted

Reference Number: EMA/CHMP/396710/2018

English (EN) (64.65 KB - PDF)

**First published:** 29/06/2018

**Last updated:** 29/06/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-yescarta_en.pdf)

#### News on Yescarta

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 June 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024) 14/06/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022) 22/04/2022

[First two CAR-T cell medicines recommended for approval in the European Union](/en/news/first-two-car-t-cell-medicines-recommended-approval-european-union) 29/06/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-june-2018) 29/06/2018

#### More information on Yescarta

- [EU/3/14/1393 - orphan designation for treatment of diffuse large B-cell lymphoma](/en/medicines/human/orphan-designations/eu-3-14-1393)
- [EU/3/15/1553 - orphan designation for treatment of primary mediastinal large B-cell lymphoma](/en/medicines/human/orphan-designations/eu-3-15-1553)
- [EU/3/15/1579 - orphan designation for treatment of follicular lymphoma](/en/medicines/human/orphan-designations/eu-3-15-1579)
- [EMEA-002010-PIP01-16-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002010-pip01-16-m03)
- [Abecma / Breyanzi / Carvykti / Kymriah / Tecartus / Yescarta - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/abecma-breyanzi-carvykti-kymriah-tecartus-yescarta)
- [Molecular profiling of tissue samples from patients who received a Kite-manufactured gene-modified cell therapy and have developed a secondary malignancy of T-cell origin - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000769)
- [Implementation of controlled access to and distribution of medicinal products in European Union (CONTROL-EU) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000313)
- [Long-term, Non-interventional Study of Recipients of Yescarta® for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, and Follicular Lymphoma - post-authorisation study](https://catalogues.ema.europa.eu/study/47191)
- [Quantitative Testing of Healthcare Provider Knowledge about YESCARTA® (axicabtagene ciloleucel) Risk Minimisation Measures - post-authorisation study](https://catalogues.ema.europa.eu/study/43134)

#### Topics

- [Advanced therapies](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A42)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/12/2025

## Share this page

[Back to top](#main-content)